Navigation Links
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Date:3/7/2012

s and kill prostate cancer cells across multiple genotypes in vitro and in vivo" (Abstract 1841; Section 30). 

Drs. Asfar Azmi and Ramzi Mohammed of Wayne State University will present two posters: "CRM-1 as a potential therapeutic target in pancreatic cancer" (Abstract 1815; Section 30) and "Novel small molecule CRM-1 inhibitor for Non Hodgkin's Lymphoma" (Abstract 1825; Section 30).

Drs. Roberto Fragomeni and James Cusack of Massachusetts General Hospital will present "Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor" (Abstract 1914; Section 34).

Drs. Christopher Walker and Danilo Perrotti of the Ohio State University will present "Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias" (Abstract 3839; Section 32).

Dr. Dilara McCauley of Karyopharm will present "Selective inhibitors of nuclear export (SINE) induce multiple tumor suppressor proteins (TSP) activity and show single agent antitumor effect and synergy with Bcl-2 antagonist in non-small cell lung cancer" (Abstract 1831; Section 30).

Dr. Yosef Landesman of Karyopharm will present a poster, "Pharmacokinetic (PK) / pharmacodynamic (PDn) and efficacy relationship of selective inhibitors of nuclear export (KPT-SINE)" (Abstract 3775; Section 30).

Karyopharm's founder and Chief Scientific Officer Dr. Sharon Shacham commented, "We are very pleased to share the results of our continuing collaborative and internal work on the mechanisms of action and anti-tumor activity of SINE compounds in the treatment of a variety of malignant conditions. We are encouraged by their activity in dogs with naturally occurring and chemotherapy refractory tumors, and we are on track to bring our first in class, oral clinical candidate into Phase 1 studies this year."

About Karyopharm

Karyopharm
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
5. Orexigen Therapeutics to Present at Upcoming Conferences
6. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Technology Applications International Corporation (the "Company" or "NUUU")(OTC ... Int,l, Inc. has signed an additional exclusive licensing agreement ... the Johnson Space Center in Houston ... Charles J. Scimeca , ... our latest, exclusive agreement with NASA. In addition to ...
(Date:9/2/2014)... Orexigen Therapeutics, Inc. (Nasdaq: OREX ... Office (PTO) has issued a patent related to NB32, ... NB32 is a fixed-dose combination of naltrexone sustained release ... 8,815,889 claims methods for treating insulin resistance using a ... 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the United States ... the Company in the month of August that are ... The issued patents are: ... issued August 19, 2014; and , U.S.RE45,095 issued ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... AdvanceBio LLC, a Cincinnati-based advanced biofuel technology company, ... fuel ethanol process. The process is capable ... sugar beet and other similar crops as feedstock for ... generating zero liquid waste. When built in ...
... TIRAT CARMEL, Israel, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Aug. 30 Marrone Bio Innovations (MBI) ... for the control of invasive mussels, at the ... San Diego, California, August 29 to September 2, 2010. ... representing academia, industry, government agencies, NGOs and other stakeholders ...
Cached Biology Technology:Zero Discharge Sweet Sorghum Ethanol Process Development 2InSightec Treats First Prostate Cancer Patients in Clinical Trials 2InSightec Treats First Prostate Cancer Patients in Clinical Trials 3InSightec Treats First Prostate Cancer Patients in Clinical Trials 4InSightec Treats First Prostate Cancer Patients in Clinical Trials 5InSightec Treats First Prostate Cancer Patients in Clinical Trials 6InSightec Treats First Prostate Cancer Patients in Clinical Trials 7InSightec Treats First Prostate Cancer Patients in Clinical Trials 8Marrone Bio Innovations to Present Invasive Mussel Control Solution 2
(Date:9/2/2014)... With their long, spiky legs and their propensity for ... stuff of nightmares. And now research from North Carolina ... spread into homes across the eastern United States. , ... or pose any kind of threat to humans," says ... State and lead author of a paper about the ...
(Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... Who is related to whom, who begat whom, how did ... reptiles. In 2011, his fieldwork in Sri Lanka studying ... identity of 60 known species of snakes. With Sri Lankan ... amphibians and reptiles, and Dushantha Kandambi, a local naturalist and ...
... Copenhagen, Denmark, Shenzhen, China. Tue., 12 March 2013 ... world,s largest genomics organization, will be working together aiming ... genomics and bioinformatics capabilities of both institutions. This partnership ... food security, energy and health. , Prof Richard Cogdell, ...
... to have an ambiguous, obscure or hidden meaning. In ... are hidden inside their genes. Two University of ... tiny clams, long believed to be members of the ... along the rocky shores of southern Australia for millions ...
Cached Biology News:Sri Lankan snake study reveals new species, rich biodiversity in island country 2BGI and TGAC join efforts to tackle global challenges in food security, energy and health 2Cryptic clams: U-M biologists find species hiding in plain view 2Cryptic clams: U-M biologists find species hiding in plain view 3
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
...
...
Biology Products: